Anti-biofilm antibiotics
Anti-biofilm antibiotics has been studied in 1 paper since 2024: 1 observational study in people. The newest paper, Oct 1, 2024: “"Implant-associated infection after hip fracture surgery in elderly patients: Risk factors and mortality"”.
1 paper studies it2 findingsUpdated
See all 1 papers on anti-biofilm antibiotics
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Receiving anti-biofilm antibiotics for more than 2 weeks was associated with less treatment failure (OR:0.32; [95 %CI: 0.13-0.80])”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Australian Research Council and 1 more
- Humans1
What did studies of anti-biofilm antibiotics find?
1Studies of anti-biofilm antibiotics measured one outcome, implant-related infection.
Implant-related infection
downin humans1OR 0.32
1 study
Implant-related infection
downin humans1OR 0.32
Anti-biofilm antibiotics are linked with lower implant-related infection in humans (implant-related infection following hip fracture) (OR 0.32, 95% CI 0.13-0.80).
“Receiving anti-biofilm antibiotics for more than 2 weeks was associated with less treatment failure (OR:0.32; [95 %CI: 0.13-0.80])”
Humansimplant-related infection following hip fracture>2 weeks
Injury
What is anti-biofilm antibiotics linked with?
1Studies link anti-biofilm antibiotics with mortality.
Mortality
downin humans1OR 0.22
1 study
Mortality
downin humans1OR 0.22
Anti-biofilm antibiotics are linked with a lower risk of mortality in humans (implant-related infection following hip fracture) (OR 0.22, 95% CI 0.08-0.60).
“Receiving anti-biofilm antibiotics for more than 2 weeks was associated with less treatment failure (OR:0.32; [95 %CI: 0.13-0.80]) and 12-month mortality (OR:0.22 [95 %CI: 0.08-0.60]).”
Humansimplant-related infection following hip fracture>2 weeks
Injury